Tafasitamab is a CD19-directed cytolytic monoclonal antibody used in the treatment of B-cell malignancies. It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytotoxicity relative to non-engineered anti-CD19...
- Mechanism
- Curator reviewed · 4 references
The CD19 surface antigen is a protein expressed on the surface of pre-B and mature B-lymphocytes that appears to play a role in enhancing B-cell receptor signaling and is considered integral to their survival. These surface proteins are also highly expressed on several B-cell malignancies, such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and diffuse large B-cell lymphoma (DLBCL).
Tafasitamab is a CD19-directed cytolytic monoclonal antibody that, upon binding and blocking the activity of CD19, causes lysis of B-cells. This process is mediated through both direct apoptosis and immune-mediated effector mechanisms, such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).
- Primary indication
- Tafasitamab is indicated, in combination with lenalidomide, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified whom are ineligible for autologous stem cell transplant (ASCT).Curator reviewed · 4 structured indications
- Formula / weight
- 150000.0 Da
- First approval
- Canada, 2021 · United States, 2020 · European Union, 2021
- Also known as
- tafasitamab-cxix
- Code names
- INCMOR00208 · MOR-00208 · MOR-208 · WHO 10835 · XmAb-5574
- Brand names
Resolves to
What you can answer from here — as of May 12, 2026
Which drugs share a target with Tafasitamab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account